# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

> **NCT02622334** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 45 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Latanoprost
- **DRUG:** Placebo
- **DRUG:** RO5093151

## Key facts

- **NCT ID:** NCT02622334
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-29
- **Primary completion:** 2016-07-28
- **Final completion:** 2016-07-28
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02622334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02622334, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02622334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*